(2S,4R)-1-((S)-23-amino-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide dihydrochloride

Catalog No. :
ACEIAU521
CAS No. :
2763910-08-1
Molecular Formula :
C36H59Cl2N5O10S
Molecular Weight :
824.87

IUPAC Name:(2S,4R)-1-((S)-23-amino-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide dihydrochloride

(2S,4R)-1-((S)-23-amino-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide dihydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(2S,4R)-1-((S)-23-amino-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide dihydrochloride
IUPAC Name(2S,4R)-1-((S)-23-amino-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide dihydrochloride
Molecular FormulaC36H59Cl2N5O10S
Molecular Weight824.87
SMILESCC1=C(C2=CC=C(CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC(=O)COCCOCCOCCOCCOCCOCCN)C(C)(C)C)C=C2)SC=N1.Cl.Cl
InChI KeyBKJZEZIKOYDRIF-CTFBPPBLSA-N
CAS No.2763910-08-1

Synthetic Route by SureRoute

1. ACEIAU521 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAZNH420 route compound structure diagram
    ACAZNH4202086298-71-5 In Stock
  2. Then
  3. ACEIAU521 route product structure diagram
    ACEIAU5212763910-08-1
Inquiry

2. ACEIAU521 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEIAU521 route product structure diagram
    ACEIAU5212763910-08-1
Inquiry

Comments (0)